Advertisement

Toxicity Management for Head and Neck Tumors in Radiation Oncology-II

  • Pervin Hurmuz
Chapter
  • 34 Downloads

Abstract

Radiation therapy (RT) is used widely for the treatment of head and neck tumors. The protection of organs at risk (OAR) in the head and neck region is crucial in cancer survivors. This chapter will outline the pathophysiology of radiation-induced toxicity, biologic and clinical principles of head and neck tolerance to radiation, and the treatment strategies of both acute and chronic radiation-induced head and neck toxicity.

Keywords

Head and neck radiation toxicity Radiotherapy Treatment 

References

  1. 1.
    Heyd C, Yellon R. Anatomy head and neck, pharynx muscles. Treasure Island: StatPearls; 2019.Google Scholar
  2. 2.
    Sakamoto Y. Gross anatomical observations of attachments of the middle pharyngeal constrictor. Clin Anat. 2014;27(4):603–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Lengele B, Hamoir M, Scalliet P, Gregoire V. Anatomical bases for the radiological delineation of lymph node areas. Major collecting trunks, head and neck. Radiother Oncol. 2007;85(1):146–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Shaw SM, Martino R. The normal swallow: muscular and neurophysiological control. Otolaryngol Clin North Am. 2013;46(6):937–56.PubMedCrossRefGoogle Scholar
  5. 5.
    Mu L, Sanders I. Neuromuscular compartments and fiber-type regionalization in the human inferior pharyngeal constrictor muscle. Anat Rec. 2001;264(4):367–77.PubMedCrossRefGoogle Scholar
  6. 6.
    Tsumori N, Abe S, Agematsu H, Hashimoto M, Ide Y. Morphologic characteristics of the superior pharyngeal constrictor muscle in relation to the function during swallowing. Dysphagia. 2007;22(2):122–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Brouwer CL, Steenbakkers RJ, Bourhis J, et al. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG oncology and TROG consensus guidelines. Radiother Oncol. 2015;117(1):83–90.PubMedCrossRefGoogle Scholar
  8. 8.
    Genovesi D, Perrotti F, Trignani M, et al. Delineating brachial plexus, cochlea, pharyngeal constrictor muscles and optic chiasm in head and neck radiotherapy: a CT-based model atlas. Radiol Med. 2015;120(4):352–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Harari PM, Song S, Tome WA. Emphasizing conformal avoidance versus target definition for IMRT planning in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010;77(3):950–8.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Schwartz DL, Hutcheson K, Barringer D, et al. Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(5):1356–65.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Caglar HB, Tishler RB, Othus M, et al. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(4):1110–8.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Caudell JJ, Schaner PE, Desmond RA, Meredith RF, Spencer SA, Bonner JA. Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2010;76(2):403–9.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Eisbruch A, Kim HM, Feng FY, et al. Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. Int J Radiat Oncol Biol Phys. 2011;81(3):e93–9.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Li B, Li D, Lau DH, et al. Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapy. Radiat Oncol. 2009;4(1):52.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Hutcheson KA, Lewin JS, Barringer DA, et al. Late dysphagia after radiotherapy-based treatment of head and neck cancer. Cancer. 2012;118(23):5793–9.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Choi M, Refaat T, Lester MS, Bacchus I, Rademaker AW, Mittal BB. Development of a standardized method for contouring the larynx and its substructures. Radiat Oncol. 2014;9:285.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Lazarus CL. Effects of chemoradiotherapy on voice and swallowing. Curr Opin Otolaryngol Head Neck Surg. 2009;17(3):172–8.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Rancati T, Schwarz M, Allen AM, et al. Radiation dose-volume effects in the larynx and pharynx. Int J Radiat Oncol Biol Phys. 2010;76(Suppl 3):S64–9.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys. 2004;60(5):1425–39.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Jensen K, Lambertsen K, Grau C. Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer: frequency, intensity and correlation with dose and volume parameters. Radiother Oncol. 2007;85(1):74–82.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F. Radiotherapy toxicity. Nat Rev Dis Primers. 2019;5(1):13.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Sourati AAA, Malekzadeh M. Laryngeal edema. In: Acute side effects of radiation therapy. Cham: Springer; 2017.CrossRefGoogle Scholar
  23. 23.
    Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer. 2006;6(9):702–13.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Khanna A. DNA damage in cancer therapeutics: a boon or a curse? Cancer Res. 2015;75(11):2133–8.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–22.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Grande C. Hypothyroidism following radiotherapy for head and neck cancer: multivariate analysis of risk factors. Radiother Oncol. 1992;25(1):31–6.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Kim MY, Yu T, Wu H-G. Dose-volumetric parameters for predicting hypothyroidism after radiotherapy for head and neck cancer. Jpn J Clin Oncol. 2014;44(4):331–7.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Cella L, Conson M, Caterino M, et al. Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1802–8.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Fujiwara M, Kamikonya N, Odawara S, et al. The threshold of hypothyroidism after radiation therapy for head and neck cancer: a retrospective analysis of 116 cases. J Radiat Res. 2015;56(3):577–82.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Alterio D, Jereczek-Fossa BA, Franchi B, et al. Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: a retrospective analysis of seventy-three patients. Int J Radiat Oncol Biol Phys. 2007;67(1):144–50.PubMedCrossRefGoogle Scholar
  31. 31.
    Miller MC, Agrawal A. Hypothyroidism in postradiation head and neck cancer patients: incidence, complications, and management. Curr Opin Otolaryngol Head Neck Surg. 2009;17(2):111–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Nishiyama K, Tanaka E, Tarui Y, Miyauchi K, Okagawa K. A prospective analysis of subacute thyroid dysfunction after neck irradiation. Int J Radiat Oncol Biol Phys. 1996;34(2):439–44.PubMedCrossRefGoogle Scholar
  33. 33.
    Khandelwal D, Tandon N. Overt and subclinical hypothyroidism. Drugs. 2012;72(1):17–33.PubMedCrossRefGoogle Scholar
  34. 34.
    Bhandare N, Kennedy L, Malyapa RS, Morris CG, Mendenhall WM. Primary and central hypothyroidism after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys. 2007;68(4):1131–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Ozawa H, Saitou H, Mizutari K, Takata Y, Ogawa K. Hypothyroidism after radiotherapy for patients with head and neck cancer. Am J Otolaryngol. 2007;28(1):46–9.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Murtha AD, Knox SJ, Hoppe RT, Rupnow BA, Hanson J. Long-term follow-up of patients with stage III follicular lymphoma treated with primary radiotherapy at Stanford University. Int J Radiat Oncol Biol Phys. 2001;49(1):3–15.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med. 1991;325(9):599–605.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Jereczek-Fossa BA, Alterio D, Jassem J, Gibelli B, Tradati N, Orecchia R. Radiotherapy-induced thyroid disorders. Cancer Treat Rev. 2004;30(4):369–84.PubMedCrossRefGoogle Scholar
  39. 39.
    Bakhshandeh M, Hashemi B, Mahdavi SR, Nikoofar A, Edraki HR, Kazemnejad A. Evaluation of thyroid disorders during head-and-neck radiotherapy by using functional analysis and ultrasonography. Int J Radiat Oncol Biol Phys. 2012;83(1):198–203.PubMedCrossRefGoogle Scholar
  40. 40.
    Bekkering GE, Agoritsas T, Lytvyn L, et al. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ. 2019;365:l2006.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988–1028.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215–28.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Hall WH, Guiou M, Lee NY, et al. Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2008;72(5):1362–7.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Thomas TO, Refaat T, Choi M, et al. Brachial plexus dose tolerance in head and neck cancer patients treated with sequential intensity modulated radiation therapy. Radiat Oncol. 2015;10(1):94.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Bowen BC, Verma A, Brandon AH, Fiedler JA. Radiation-induced brachial plexopathy: MR and clinical findings. Am J Neuroradiol. 1996;17(10):1932–6.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Gillette EL, Mahler PA, Powers BE, Gillette SM, Vujaskovic Z. Late radiation injury to muscle and peripheral nerves. Int J Radiat Oncol Biol Phys. 1995;31(5):1309–18.PubMedCrossRefGoogle Scholar
  47. 47.
    King SN, Dunlap NE, Tennant PA, Pitts T. Pathophysiology of radiation-induced dysphagia in head and neck cancer. Dysphagia. 2016;31(3):339–51.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Delanian S, Lefaix JL, Pradat PF. Radiation-induced neuropathy in cancer survivors. Radiother Oncol. 2012;105(3):273–82.PubMedCrossRefGoogle Scholar
  49. 49.
    Delanian S, Lefaix JL. Current management for late normal tissue injury: radiation-induced fibrosis and necrosis. Semin Radiat Oncol. 2007;17(2):99–107.PubMedCrossRefGoogle Scholar
  50. 50.
    Glantz MJ, Burger PC, Friedman AH, Radtke RA, Massey EW, Schold SC. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology. 1994;44(11):2020.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(13):2545–50.CrossRefGoogle Scholar
  52. 52.
    Hamama S, Gilbert-Sirieix M, Vozenin MC, Delanian S. Radiation-induced enteropathy: molecular basis of pentoxifylline-vitamin E anti-fibrotic effect involved TGF-beta1 cascade inhibition. Radiother Oncol. 2012;105(3):305–12.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Pervin Hurmuz
    • 1
  1. 1.Faculty of Medicine, Department of Radiation OncologyHacettepe UniversityAnkaraTurkey

Personalised recommendations